Ainur Yusniza Yusof1*, Siti Asma Bakar1, Siti Ummyrah Rosley1, Nur Syahirah Alias1, Bavithra Venu1, Siti Fatimah Abdullah1
1. Autoimmune Unit, Allergy and Immunology Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Malaysia, Setia Alam, 40170 Shah Alam, Selangor
*Corresponding author: Ainur Yusniza Yusof.
ABSTRACT
INTRODUCTION: Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in non-diabetic adults, with primary MN (PMN) accounting for 70-80% of all MN cases. Serum anti-phospholipase A2 receptor (PLA2R) antibodies serve as diagnostic and prognostic biomarkers for PMN, with a high prevalence reported among Chinese and Korean populations.
OBJECTIVE(S): This retrospective study aimed to determine the seropositivity of anti-PLA2R antibodies among the Malaysian population with suspected PMN.
MATERIALS & METHODS: A total of 648 serum samples collected from patients with suspected PMN at state hospitals across Malaysia between January and December 2024 were analysed. These samples were tested for anti-PLA2R antibodies using the EUROIMMUN Anti-PLA2R ELISA (IgG) kit. The assay utilised microtitre strips with reagent wells pre-coated with recombinant PLA2R antigen.
RESULTS: The mean age of subjects was 54.7 years (range 20-74 years), with a male-to-female ratio of 2:1. Out of 648 subjects, 66 (10.18%) were positive for anti-PLA2R antibodies, while 3 (0.46%) showed borderline results. Ethnic distribution showed the highest proportion among Chinese (n = 27; 41.0%), followed by Indians (n = 19; 28.8%), Malays (n = 14; 21.2%), and others (n = 6; 9.1%).
CONCLUSION: This study demonstrates a low seropositivity rate of anti-PLA2R antibodies among suspected PMN cases in Malaysia, with a predominance in males and the highest prevalence observed in the Chinese ethnic group. These findings are consistent with previous studies conducted in Chinese and Korean populations.
KEYWORDS: Membranous Nephropathy, Primary Membranous Nephropathy, Phospholipase A2 Receptor, Biomarker, Antibodies


